Prudential Financial Inc. Has $1.46 Million Position in Vera Therapeutics, Inc. $VERA

Prudential Financial Inc. cut its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 25.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 62,037 shares of the company’s stock after selling 21,540 shares during the quarter. Prudential Financial Inc. owned about 0.10% of Vera Therapeutics worth $1,462,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Trexquant Investment LP increased its position in Vera Therapeutics by 187.1% during the first quarter. Trexquant Investment LP now owns 62,777 shares of the company’s stock worth $1,508,000 after buying an additional 40,913 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Vera Therapeutics in the first quarter worth about $326,000. Russell Investments Group Ltd. boosted its stake in shares of Vera Therapeutics by 505.1% during the 1st quarter. Russell Investments Group Ltd. now owns 152,918 shares of the company’s stock worth $3,673,000 after acquiring an additional 127,646 shares in the last quarter. EFG Asset Management North America Corp. raised its stake in shares of Vera Therapeutics by 49.4% in the 1st quarter. EFG Asset Management North America Corp. now owns 109,281 shares of the company’s stock valued at $2,623,000 after acquiring an additional 36,121 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new stake in Vera Therapeutics in the 2nd quarter worth approximately $102,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. TD Cowen increased their price target on Vera Therapeutics from $60.00 to $73.00 and gave the company a “buy” rating in a report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a report on Friday, November 28th. JPMorgan Chase & Co. dropped their target price on shares of Vera Therapeutics from $53.00 to $52.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. Pivotal Research set a $73.00 target price on shares of Vera Therapeutics in a research report on Friday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Vera Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $63.18.

Insider Buying and Selling at Vera Therapeutics

In other news, SVP Joseph R. Young sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the sale, the senior vice president directly owned 47,839 shares in the company, valued at approximately $1,390,201.34. The trade was a 23.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 16.30% of the company’s stock.

Vera Therapeutics Stock Up 5.4%

Shares of VERA opened at $44.90 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. The company has a 50-day simple moving average of $30.37 and a 200-day simple moving average of $25.49. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $49.77. The firm has a market capitalization of $2.87 billion, a P/E ratio of -11.25 and a beta of 1.21.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same quarter in the previous year, the company posted ($0.85) earnings per share. On average, equities research analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.